Monday October 19, 2020 0 comments
BOULDER -- Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of R. Michael Carruthers to the newly created position of chief financial officer (CFO).
Carruthers brings more than two decades of experience serving as CFO for publicly-traded biopharmaceutical companies, with extensive experience across corporate finance and strategic planning including initial public offerings, capital raising strategy and mergers and acquisitions.
Carruthers’ appointment comes at an important time as Edgewise advances EDG-5506, the company’s lead product candidate, in clinical development for Duchenne and Becker muscular dystrophy (DMD and BMD).
“Mike brings a deep understanding of financial strategy in the biopharmaceutical industry and his business and financial expertise will be instrumental as we advance our company,” said Kevin Koch, president and CEO, Edgewise Therapeutics.
“Having worked with Mike previously, I know that he will be an outstanding member of our executive team as we progress our pipeline.”
“I’m excited to join Edgewise at this pivotal point in the company’s growth and to support the advancement of EDG-5506, a potentially transformative product candidate in DMD,” said Carruthers.
Prior to joining Edgewise, Carruthers served as fractional CFO for several private and public companies. Previously, he served as interim president of Nivalis Therapeutics, a publicly traded company that merged with Alpine Immune Sciences, in 2017 and CFO and secretary since 2015.
From 1998 to 2015, he served as CFO for Array BioPharma Inc., a publicly traded company acquired by Pfizer Inc. Prior to this, he served as CFO of Sievers Instruments, treasurer and controller for the Waukesha division of Dover Corporation and accountant with Coopers & Lybrand.
Carruthers received a B.S. in accounting from the University of Colorado and a M.B.A. from the University of Chicago.